CO-EXHIBITING · 2019-05-06 · - HCS and phenotypic screening. Secondary focus on HCS- and HT...

FRENCH PAVILION BOOTH N° 2109

BIO PHILADELPHIAJUNE 3-6

CO-EXHIBITING COMPANIES

AND PARTNERS

TABLE OF CONTENTS

22


AND PARTNERSALIZÉ PHARMA 3 ...........................................................05

ANS BIOTECH ................................................................06

BD ....................................................................................07

BIOFILM PHARMA .........................................................08

CARTHERA .....................................................................09

CEA LETI .........................................................................10

CYTOO .............................................................................11

ELSALYS BIOTECH ........................................................12

GENOWAY .......................................................................13

NETRI ..............................................................................14

NEURONAX ....................................................................15

NOVADISCOVERY ..........................................................16

PREDICTION BIOSCIENCES .........................................17

ROOWIN ..........................................................................18

SIGNIA THERAPEUTICS ...............................................19

SOLADIS .........................................................................20

TRANSCURE BIOSERVICES .........................................21

LIFE SCIENCES IN AUVERGNE-

RHÔNE-ALPES Auvergne-Rhône-Alpes, the 1st region in france for future of medecine …………………………………………………………… 24

Lyonbiopole, the gateway to healthcare innovation …………………………………………………………………………………………… 25

Only Lyon, Life Sciences a driving force for Lyon's economy ……………………………………………………………………………… 27

Biopole Clermont Limagne ………………………………………………………………………………………………………………………………… 29

3

TABLE OF CONTENTS

3


AND PARTNERS

ECONOMIC PLAYERS

This year in Philadelphia,17

representing the industrial & scientific strengths of the Auvergne-Rhône-Alpes region, under the banner of Lyonbiopole.

4

55

Alizé Pharma 3 develops innovative therapeutic peptides for rare endocrine and metabolic diseases. Its ambition is to become a leading company in rare diseases with operations in both the US and Europe to support the global development of products.

Alizé Pharma 3 is building an innovative and balanced portfolio of products targeting significant unmet medical needs. Its first two assets are AZP-3601, a best-in-class PTH analog for hypoparathyroidism, and AZP-3404, a peptide leveraging the biology of IGFBP2 for the treatment of syndromes of severe insulin resistance.

Contact: Thierry ABRIBATPRESIDENT & CEO

15, chemin du Saquin F - 69130 ECULLY

Tel: +33 (0)4 72 18 94 28E-mail: [email protected]

www.alz-pharma.com

Contact: François CAUSSADECEO

20 - 22, rue Henri et Gilberte GoudierF - 63200 RIOM


www.ans-biotech.com

ANS Biotech, a preclinical CRO dedicated to the in vivo pharmacology of pain, offers a unique combination of exceptional expertise in the fundamentals of pain pharmacology and a proven record of R&D program management for the new and innovative analgesics of its clients.

Our mission is to support the drug discovery and development efforts of companies involved in human and animal health, food and nutrition, by offering a broad range of consulting services and a growing list of clinically relevant disease and efficacy models.

As a close Pharma and Biotech partner, we commit to providing cost-effective preclinical pharmacology services performed to the highest ethical and quality standards. Our customized scientific studies can help to establish proof of concept & mechanism of action for drug candidates.

6

Contact: Claire RAYNAL-OLIVEAssociate Director Strategic Innovation

11, rue Aristide Berges F - 38800 LE PONT-DE-CLAIX


www.drugdeliverysystems.bd.com

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

As a partner of choice for the pharmaceutical and biotech companies across the globe, BD Medical - Pharmaceutical Systems provides a broad range of ready-to-use drug delivery systems including glass and plastic prefillable syringes, safety and shielding systems, self-injection systems and connected solutions that help ensure smooth delivery, regardless of drug complexity, viscosity and dosing volume. We support product launch and life cycle management through sophisticated consultative, analytical and clinical services to help ensure drug compatibility and seamless systems integration, while accelerating time-to-market and reducing risk.

7

Contact: Thierry BERNARDICEO

Rue Emile Duclaux - Biopole Clermont-LimagneF - 63360 SAINT-BEAUZIRE


www.biofilmpharma.fr

BioFilm Pharma develops a new class of drugs focused on biofilm-related chronic infections and biofilm-induced antibiotic resistance, nor antibiotics neither BLI. Our technology is the first to detect and quantify biofilm formation at the earliest stage, and is protected by 10 patent families. We are preparing a Series A raise to finance a discovery platform for radically new antimicrobial drugs which inhibit biofilm formation without killing bacteria. We strongly believe that these “antibiofilms” will be to chronic infections what antibiotics have been to acute infections. Our first drug candidate should start CMC at end 2019. Both projects’ first applications are the diabetic foot ulcer (direct costs of $10bn/year, US only) and lung infections from cystic fibrosis (> $1bn/year). Next: microbiome modulator drugs!

BioFilmPharma

+

8

CarThera is a clinical stage biotech company developing innovative treatments for patients with brain diseases.

CarThera is developing a pipeline of novel treatments for brain diseases based on our patented technology.

Our lead program SC9-GBM is currently being evaluated in a global phase 1/2 trial and is poised to start a pivotal clinical trial in glioblastoma in 2020.We have recently initiated another phase 1/2 trial with SC1-MET in melanoma brain metastases.

SC1-ALZ is also being evaluated in an investigator-led proof-of-concept clinical trial in patients with Alzheimer’s disease.

All our programs are based on our SonoCloud technology, a first-in-class solution to safely increase brain concentration of therapeutic agents with multiple indications in oncology, neurology and rare diseases.

Contact: Frederic SOTTILINICEO

BioParc - 60, avenue RockefellerF - 69002 LYON


www.carthera.eu

9

Contact: Alexandre THERMETNorth America Manager, Strategic Industrial Partnerships at Leti-Health Dpt

Minatec campus - 17, rue des Martyrs F - 38054 GRENOBLE CEDEX 9

Tel: 1 (510) 331 3859E-mail: [email protected]

www.cea-leti.fr

Leti is a technology research institute at CEA Tech. Leti-Health regroups 250 researchers, technicians, engineers and clinicians working in the Technology for Biology and Health Department and Clinatec, a novel pre-clinical and clinical platform developed with the University hospital.

Together with our industrial, clinical and academic partners, we address the following application domains: in vitro diagnostics and monitoring for health, environment, life science, manufacturing and CBRN, therapeutics, nanomedicine and implanted medical devices and imaging systems. Our strategy is to serve the industry and answer to the health challenges, going toward miniaturization, multi-modality and connected devices, delivering prototypes “ready to transfer”, i.e. compliant with industrial standards and medical regulations.

10

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates.

CYOO has developed MyoScreen, a fully mature human in vitro muscle model derived from primary human samples (healthy and pathological myoblasts) for generating NCEs and identifying new targets from a variety of pathological conditions (rare, chronic).

CYTOO’s know-how and expertise portfolio includes:- patient cells sourcing and donor profiling;- disease modeling;- custom assay development (including expertise in image analysis);- HCS and phenotypic screening.

Secondary focus on HCS- and HT compatible skin models (atopic dermatitis, psoriasis).

Contact: Christophe POQUETBusiness Development Manager

7, parvis Louis Néel - Minatec - BHT - Bat. 52F - 38040 GRENOBLE

Tel: +33 (0)4 38 88 47 05 E-mail: [email protected]

www.cytoo.com

11

Contact: Christine GUILLENCEO

317, avenue Jean Jaurès F - 69007 LYON


www.elsalysbiotech.com

ELSALYS BIOTECH is a pharmaceutical company which develops new generation antibodies to modulate the immune system of patients with cancer or rare haematological diseases.

Its mission is at the heart of personalised and precision medicine where the ultimate goal is to increase the proportion of responders to new treatments.

Today ELSALYS BIOTECH is conducting 5 proprietary development programs including Inolimomab (LEUKOTAC®), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease.

12

genOway has developed a unique platform of preclinical models for profiling of immune targeting agents in Immuno-Oncology and Immuno-Inflammation. These models enable the evaluation of biologics in a context of well calibrated syngeneic tumors (h- VISTA, hPD-1, hCTLA-4, hCD28, hGITR, h4-1BB, hTIM-3/hPD-1, etc.) or the use of Xenograft tumors (Human Immune System mice). All models are provided with the necessary freedom to operate: genOway holds exclusive IP on key technologies, such as the knock-in and the CRISPR/Cas9. Moreover, genOway offers access to 2000 models of target validation and compound specificity assessment. After 20 years of interaction with 17 of the top 20 pharmaceutical companies and numerous renowned biotech companies, genOway has gathered a tremendous experience in preclinical model development.

Contact: Kader THIAMVP Transgenic Technologies

31, rue Saint-Jean-de-DieuF - 69007 LYON


www.genoway.com

13

Contact: Thibault HONEGGERChief Science Officer, President

321, avenue Jean Jaurès F - 69007 LYON


www.netri.fr

At NETRI, we design, fabricate and exploit 3D microfluidic chips to reproduce neural circuits. NETRI is a young company-private research institute that aims at understanding the structural and functional mechanistic of neural circuits, neurological disorders or potential novel treatments. Using a multi compartment approach, we can reproduce in our devices complex circuits (up to 7 interconnected neural populations). The “organ on chip” approach allows us to provide physiologically relevant platforms for neuroscience. Our ex-vivo models are used with a wide range of cell lines (rodent, human primary cells or iPSCs). We collaborate with pharmaceutical companies, CROs, academic researchers and medical doctors to accelerate the understanding of neural troubles mechanisms and the discoveries of new treatments.

14

Neuronax is a biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs.

Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders.

NX210, our lead product, is a first-in-class multi-target peptide with high potential and promising preclinical results in many CNS disorders.

Contact: Manuel BLANCChief Scientific Officer

60, avenue RockefellerF - 69008 LYON


www.neuronax.com

15

Contact: Julie PITRATBusiness Development Manager

1, Place Verrazzano F - 69009 LYON


www.novadiscovery.com

Novadiscovery is specialized in clinical trials, prediciting clinical efficacy of drug candidates before human trials.

In silico clinical trials are a new paradigm in our industry, de-risking drug R&D while decreasing time and cost of development. Based on knowledge extracted from literature and data, we build mathematical models of disease and treatment. Then, to simulate a trial, we run those models on virtual patients to predict the clinical efficacy of new drugs at the population level. Using these techniques and workflow, we have already helped several companies accelerate their drug development. The FDA already gave its agreement in principles for one of our client to entirely skip a phase II and decrease the trial size of their phase III from +10,000 to 500 patients thanks to the use of in silico.

16

Prediction BioSciences is a R&D Company located in the dynamic environment of Lyon. The goal of the Company is to develop and bring to clinical phase or market appropriate solutions in the field of cardiovascular and neurology.

The firm utilizes innovative blood biomarkers to investigate and develop new diagnostic where unmet medical needs are faced. It has a deep diagnostic pipeline which benefits from strong IP protection in cardiovascular field. The Company also runs a drug development program in the field of stroke, in partnership with a CDMO. That project was awarded by the European Eurostars program call for proposal no17.

Lately, the Company launched a drug discovery program in the field of neurodegenerative diseases.

Contact: Cornelius DIAMONDPresident

Batiment Laennec - 60, avenue RockefellerF - 69008 LYON


www.predict.net

17

Contact: Patrice ROOLChief Executive Officer

20, rue Henri Goudier F - 63200 RIOM


www.roowin.com

Our core business being in high value-added fine chemistry, we offer a large range of chemical services and a single CMC one-stop shopping.

We support our customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches (about 20 kg).

We deliver customized services and therapeutic development programs with their essential biopharmaceuticals for all phases of your projects:- Drug discovery- Lead optimization- Process development/optimization- GMP synthesis - Analytical services (method development, validation, stress study, stability study)- Impurities carry over- IND/IMPD file

We are very concerned by very tight timeline and quality. We are GMP approved since 2007 and last inspection in December 2016.

18

Signia Therapeutics has developed a breakthrough strategy to reposition rapidly & at low cost commercially available or shelved drugs (from proprietary libraries) in new anti-infectious indications, especially against respiratory viruses. Signia Therapeutic’s drug discovery platform is based on analysis of transcriptomic signatures. This platform has demonstrated its potential with eight repurposed molecules, pre-clinically validated as new antivirals (flu, RSV, hMPV and MERS), protected by international patents, and available for out-license. One of the molecule repositioned by Signia Therapeutics is currently in Phase II clinical trial in severe flu, aiming to include 176 patients, with results expected mid 2020. Signia Therapeutics platform will continuously propose new drug candidates in infectious diseases.

Contact: Philippe PERSONNEPresident

43, boulevard du 11 novembre 1918F - 69100 VILLEURBANNE


www.signiatherapeutics.com

19

Contact: Olivier SCHWARTZBusiness & Innovation Manager

6 et 8, rue Bellecombe F - 69006 LYON


www.soladis.com

Soladis is a reliable partner (created in 2000) with strong expertise in health data (IA & algorithm development, Stat Methodology, data acquisition, exploration, analysis, valorization, visualisation) in Life Science. We are present in France, Switzerland, the USA and Canada.

Our services are structured on:- Studies design (statistical methodologies, acquisition methods, sample size,

etc.)- Data collection (through IoT, Web Scraping, eCRF Tools, etc.)- Data analysis (with statistical models, Machine Learning algorithms, etc.)- Reporting (interactive dashboards, webapp, clinical report, scientific article,

etc.)

Working on various topics: R&D, Industry, Real World Data...

Our team integrates statisticians, biostatisticians, bioinformaticians, biologist, clinicians, physicians, CRAs, Data Scientists...

GROUP

20

TransCure bioServices offers pre-clinical contract research services to pharmaceutical, biotech and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed animal models with fully functional human immune system have been developed to provide predictive in vivo pharmacology testing in the field of immuno-onco and onco, PDX, inflammation (IBD, SLE, MS, RA), autoimmune, anti-infective (HIV), neglected tropical diseases (Dengue) and preclinical lead candidate selection/validation for drug and vaccine development. Our customer-oriented approach includes co-designing of experiments with customers to match their needs, diligently and carefully performing the ordered studies and providing comprehensive data analysis and reporting.

Contact: Romain GRETBusiness Development Director

260, avenue Marie CurieF - 75160 ARCHAMPS


www.tcbioservices.com

21

22

LIFE SCIENCES IN AUVERGNE-RHÔNE-ALPES

24

La R

égio

n A

uver

gne-

Rhôn

e-A

lpes

20

19 -

créd

it ph

oto

: ©M

iche

l PER

ES

1st vaccine manufacturing site in Europe

150,000 jobs & 800 SMBs in healthcare

Major research & higher education centers

20,000 students & 3600 researchers

5 university hospitals

1 international agency for research on cancer

AUVERGNE-RHÔNE-ALPES, THE 1ST REGION IN FRANCEFOR THE FUTURE OF MEDECINE

25

FOUNDERS AND BOARD MEMBERS

BOARD MEMBERS

REPRESENTING PUBLIC RESEARCH REPRESENTING PRIVATE COMPANIES

STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO

Auvergne R hône Alpes- -

THE GATEWAY TO HEALTHCARE INNOVATION

226 MEMBERS

195 INNOVATIVE COMPANIES

11 INDUSTRIAL LEADERS

20 RESEARCH & CLINICAL CENTERS

C

M

J

CM

MJ

CJ

CMJ

N

Recto Verso BIO 2019.pdf 1 29/04/2019 14:56:22

La R

égio

n A

uver

gne-

Rhôn

e-A

lpes

20

19 -

créd

it ph

oto

: ©M

iche

l PER

ES

1st vaccine manufacturing site in Europe

150,000 jobs & 800 SMBs in healthcare

Major research & higher education centers

20,000 students & 3600 researchers

5 university hospitals

1 international agency for research on cancer

AUVERGNE-RHÔNE-ALPES, THE 1ST REGION IN FRANCEFOR THE FUTURE OF MEDECINE

26

€310M of private money raised by Lyonbiopole members 94 networking & scientifc events organized & co-organized

each year by Lyonbiopole

BOOST YOUR BUSINESSIN EUROPE

INNOVATE IN A DYNAMIC ECOSYSTEM

246 R&D projects accredited by Lyonbiopole since 2005€1,07B of total investment / €437M of public funding

GO GLOBAL & ACCESS NEW MARKETS

75 companies supported around the world in 9 international missions, in 201820 SMEs supported for EU funding, in 20185 europe/international workshop organised, in 2018

GET CONNECTED TO OUR ECOSYSTEM

6 directories on line700 profils:companies & start-up;consultants et service

providers;R&D projects;research units;healthcare institutions;clinical research structures

C

M

J

CM

MJ

CJ

CMJ

N


LYON METROPOLE

CON

CEPT

ION

:

CHOOSETO MAKEYOUR OWNWAYSCHOOSE LYON, ONLY LYON

TÊTE D’OR PARK, LYON FRANCE BY DMKF PHOTOGRAPHERS

27

€310M of private money raised by Lyonbiopole members 94 networking & scientifc events organized & co-organized

each year by Lyonbiopole

BOOST YOUR BUSINESSIN EUROPE

INNOVATE IN A DYNAMIC ECOSYSTEM

246 R&D projects accredited by Lyonbiopole since 2005€1,07B of total investment / €437M of public funding

GO GLOBAL & ACCESS NEW MARKETS

75 companies supported around the world in 9 international missions, in 201820 SMEs supported for EU funding, in 20185 europe/international workshop organised, in 2018

GET CONNECTED TO OUR ECOSYSTEM

6 directories on line700 profils:companies & start-up;consultants et service

providers;R&D projects;research units;healthcare institutions;clinical research structures

C

M

J

CM

MJ

CJ

CMJ

N


Infectiology

Neurosciences

Nutrition

Oncology

E-health

Lyon metropolitan area is today one of Europe‘s most dynamic and attractive place in the field of Life Sciences & Health.

Lyon Métropole helps coordinate and densify the life sciences ecosystem on 5 priority sectors.

Clémence LABATLife Sciences DirectorGrand Lyon la métropolePhone: + 33 668 241 838 - [email protected]

CONCEPTION

60 000

2 BILLION

VACCINEPRODUCTIONCENTER in the world

ST1

1686 800

5 400

since 2005 in Lyon, by vaccinesand diagnostics companies

EUROS INVESTED

over

JOBS IN HEALTH &BIOTECHNOLOGIES SECTORSource: Acoss-Urssaf 2015 and Insee-Clap 2015

PUBLIC LABORATORIES

Researchers & Teachers-Researchers

PHD STUDENTS

CLINICAL TRIALS PERFORMED each year in the Hospices Civils de Lyon

1 400

LYON, A VIBRANT ECOSYSTEM

International Agency for Research on Cancer(IARC-WHO) - Nouveau Centre

International Trade Services: helping companies export and grow into global marketContact: Emilie Da Silva - International Business Advisor - [email protected]

www.lyon-metropole.cci.fr

30

GREEN CHEMISTRY BIOFILM DETECTION & DEVELOPMENT OF NEW ANTI-

MICROBIALS NEW CLASS OF PRODUCTS FOR THE PREVENTION OF

METABOLIC DISEASES NATURAL ALTERNATIVES TO PESTICIDE & ANTIBIOTIC

TREATMENTS ENVIRONMENTALLY FRIENDLY PEPTIDE SYNTHESIS PHARMACOLOGY OF PAIN & NEW ANALGESICS BACTERIAL AND FUNGAL BIOMASSES PRODUCTION NEW ACTIVE COSMETIC INGREDIENTS FINE CHEMISTRY HIGH THROUGHPUT GENOMIC & BIOINFORMATIC RADIOPHARMACEUTICAL DRUGS DRUG DESIGN

HIGH TECH COMPANIES HAVE ALREADY CHOSEN THE BIOPÔLE CLERMONT-LIMAGNE

An overview of their fields of work

50

SAINT-BEAUZIRE SITE CLERMONT-FERRAND SITE RIOM SITE

International Trade Services: helping companies export and grow into global marketContact: Emilie Da Silva - International Business Advisor - [email protected]

www.lyon-metropole.cci.fr

Auvergne-Rhône-Alpes, the densest biocluster in EuropeContact: Gaëlle Billon, Program Manager for Americas - [email protected]

www.espaceentreprises.rhonealpes.fr

Invest In LyonContact: Florent Gerbaud - Senior Inward Investment Manager - [email protected]

Adriana Toma Houel, Ph.D.-MBus - Inward Investment Advisor Life Sciences - [email protected] www.aderly.com

The bio entrepreneurs’ hubContact: Clémence Labat - Life Sciences Project Director - [email protected]

www.business.greaterlyon.com

PARTNERS

31

© L

yonb

iopô

le -

Réa

lisat

ion:

GO

PÉ

KEEP IN

TOUCH

WITH OUR

COMMUNITY

COMPANIES &START-UPS

RESEARCH UNITS

HEALTHCARE INSTITUTIONS

R&D PROJECTS


BOARD MEMBERS


STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO



w w w . l y o n b i o p o l e . c o mw w w . l y o n b i o p o l e . c o m


BOARD MEMBERS


STATE AND LOCAL

SUPPORTSGOVERNMENTS

PARTNERS FOR BIO



226 MEMBERS

195 INNOVATIVE COMPANIES

11 INDUSTRIAL LEADERS

20 RESEARCH & CLINICAL CENTERS

C

M

J

CM

MJ

CJ

CMJ

N


CO-EXHIBITING · 2019-05-06 · - HCS and phenotypic screening. Secondary focus on HCS- and HT...

Documents

Transcript of CO-EXHIBITING · 2019-05-06 · - HCS and phenotypic screening. Secondary focus on HCS- and HT...